Table 3.

The drug survival rate at 3, 5, and 10 years of adalimumab and infliximab use

Reason for discontinuation	All reasons						Inadequate efficacy
	Adalimumab (n = 111)			Infliximab (n = 57)			Adalimumab (n = 82)			Infliximab (n = 49)
	Estimate	SE	n	Estimate	SE	n	Estimate	SE	n	Estimate	SE	N
3-year	0.52	0.48	54	0.35	0.56	25	0.57	0.55	43	0.40	0.70	17
5-year	0.43	0.49	37	0.30	0.54	18	0.50	0.58	30	0.34	0.69	12
10-year	0.14	0.50	5	0.18	0.52	6	0.22	0.75	4	0.34	0.69	4

SE standard error